Listed

Ecolab Inc.: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on May 6, 2021 and accepted by EDGAR at May 6, 2021, 16:03 ET.

Share

Management's discussion and analysis

As filed, 69,245 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following management discussion and analysis (“MD&A”) provides information we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The MD&A should be read in conjunction with both the unaudited consolidated financial information and related notes included in this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2020. This discussion contains various Non-GAAP Financial Measures and also contains various Forward-Looking Statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Statements” located at the end of Part I of this report.

Comparability of Results

ChampionX Transaction

On June 3, 2020, we completed the separation of its Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX Business, followed immediately by the merger of ChampionX (the “Merger”) with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

The ChampionX business met the criteria to be reported as discontinued operations because it is a strategic shift in business that has a major effect on our operations and financial results. Therefore, we reported the historical results of ChampionX, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations. Unless otherwise noted, the accompanying MD&A has been revised to reflect the ChampionX business as discontinued operations and all prior year balances have been revised accordingly to reflect continuing operations only.

Fixed Currency Foreign Exchange Rates

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

Impact of Acquisitions and Divestitures

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition and exclude the results of our divested businesses from the twelve months prior to divestiture. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These sales are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

OVERVIEW OF THE FIRST QUARTER ENDED MARCH 31, 2021

Sales Performance

When comparing first quarter 2021 against first quarter 2020, sales performance was as follows:

  • Reported net sales decreased 4% to $2,885 million, fixed currency sales decreased 6% and acquisition adjusted fixed currency sales decreased 8%.
  • Fixed currency sales for our Global Industrial segment decreased 2% to $1,434 million, acquisition adjusted fixed currency sales decreased 3%, reflecting unfavorable impacts in all divisions from supply chain and customer operating disruptions from the Texas freeze during the quarter, most notably in Downstream. Modest Paper sales growth and steady Water sales were more than offset by a modest Food & Beverage decline and a significant decrease in Downstream sales.
  • Fixed currency sales for our Global Institutional & Specialty segment decreased 21% to $859 million. Acquisition adjusted fixed currency sales also decreased 21%, reflecting decreases in both Specialty and Institutional that were unfavorably impacted by COVID-19’s strong second wave, as continued sanitizing product sales were more than offset by significantly reduced restaurant, lodging and entertainment facility demand for other products due to the pandemic during most of the quarter.
  • Fixed currency sales for our Global Healthcare & Life Sciences segment increased 14% to $294 million. Acquisition adjusted fixed currency sales increased 14%, driven by double-digit gains in both the Healthcare and Life Sciences segments, as both benefited from increased sales due to the COVID-19 related demand.
  • Fixed currency sales and acquisition adjusted fixed currency sales for Other decreased 3% to $271 million as a solid increase in Pest Elimination was more than offset by declines in the remaining Other segments.

Financial Performance

When comparing first quarter 2021 against first quarter 2020, our financial performance was as follows:

  • Reported operating income decreased 21% to $297 million. Excluding the impact of special (gains) and charges from both 2021 and 2020 reported results, adjusted operating income decreased 18% and our adjusted fixed currency operating income decreased 19%.
  • Net income from continuing operations attributable to Ecolab decreased 34% to $194 million. Excluding the impact of special (gains) and charges and discrete tax items from both 2021 and 2020 reported results, our adjusted net income from continuing operations attributable to Ecolab decreased 19%.
  • Reported diluted EPS from continuing operations of $0.67 decreased 33%. Excluding the impact of special (gains) and charges and discrete tax items from both 2021 and 2020 reported results, adjusted diluted EPS from continuing operations decreased 18% to $0.81 in the first quarter of 2021.
  • Our reported tax rate was 25.2% during the first quarter of 2021, compared to 13.7% during the first quarter of 2020. Excluding the tax rate impact of special (gains) and charges and discrete tax items from both 2021 and 2020 results, our adjusted tax rate was 19.7% during the first quarter of 2021, compared to 20.5% during the first quarter of 2020.

RESULTS OF OPERATIONS

Net Sales

​ ​ ​ (millions) ​ ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ ​ Change
Product and equipment sales ​ ​ $2,293.4 ​ ​ ​ $2,424.0 ​ ​ ​
Service and lease sales ​ ​ 591.6 ​ ​ ​ 596.6 ​ ​ ​
Reported GAAP net sales ​ ​ $2,885.0 ​ ​ ​ $3,020.6 ​ (4)%
Effect of foreign currency translation ​ 5.6 ​ ​ ​ 68.0 ​ ​ ​
Non-GAAP fixed currency sales ​ ​ $2,890.6 ​ ​ ​ $3,088.6 ​ (6)%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Product and sold equipment revenue is generated from providing cleaning, sanitizing and water treatment products or selling equipment used in combination with specialized products. Service and lease equipment revenue is generated from providing services or leasing equipment to customers. All of our sales are subject to the same economic conditions.

The percentage components of the period-over-period 2021 sales change are shown below:

​ ​ ​ ​ ​ ​ (percent) ​ ​ First Quarter Ended March 31 2021 ​ ​ ​
Volume ​ (10)% ​
Price changes ​ 1 ​ ​
Acquisition adjusted fixed currency sales change ​ (8) ​ ​
Acquisitions and divestitures ​ 2 ​ ​
Fixed currency sales change ​ (6) ​ ​
Foreign currency translation ​ 2 ​ ​
Reported GAAP net sales change ​ (4)% ​

Amounts do not necessarily sum due to rounding.

Cost of Sales (“COS”) and Gross Profit Margin

​ ​ ​ ​ ​ (millions/percent) ​ First Quarter Ended March 31 2021 COS ​ ​ ​ ​ ​ ​ Gross Margin ​ ​ ​ ​ ​ 2020 COS ​ ​ ​ ​ ​ ​ Gross Margin
Product and equipment cost of sales ​ $1,362.9 ​ ​ ​ ​ ​ ​ $1,364.7 ​ ​ ​ ​
Service and lease cost of sales ​ 349.1 ​ ​ ​ ​ ​ ​ 355.5 ​ ​ ​ ​
Reported GAAP COS and gross margin ​ $1,712.0 ​ ​ 40.7% ​ ​ $1,720.2 ​ ​ 43.1%
Special (gains) and charges ​ 19.6 ​ ​ ​ ​ ​ 9.1 ​ ​ ​
Non-GAAP adjusted COS and gross margin ​ $1,692.4 ​ ​ 41.3% ​ ​ $1,711.1 ​ ​ 43.4%

Our COS and corresponding gross profit margin (“gross margin”) are shown in the table above. Gross margin is defined as net sales less cost of sales divided by net sales.

Our reported gross margin was 40.7% and 43.1% for the first quarter of 2021 and 2020, respectively. Special (gains) and charges included in items impacting COS are shown within the “Special (Gains) and Charges” table on page 35.

Excluding the impact of special (gains) and charges within COS, first quarter 2021 and 2020 adjusted gross margin was 41.3% and 43.4%.

Our adjusted gross margin decreased when comparing the first quarter of 2021 against the first quarter of 2020, which was driven by COVID-19 related volume declines, the Texas freeze and an unfavorable business mix, which together more than offset the benefits of pricing.

Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expenses as a percentage of sales were 29.9% for the first quarter of 2021 compared to 30.1% for the first quarter of 2020. The first quarter SG&A ratio to sales decreased due to cost savings, partially offset by lower sales and investments in the business.

Special (Gains) and Charges

Special (gains) and charges reported on the Consolidated Statement of Income include the following items:

​ ​ ​ (millions) Cost of sales ​ ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 ​ ​ ​
Restructuring activities ​ ​ 18.2 ​ ​ ​ 3.0
Acquisition and integration activities ​ ​ - ​ ​ ​ 0.4
COVID-19 activities, net ​ ​ 1.1 ​ ​ ​ -
Other ​ ​ 0.3 ​ ​ ​ 5.7
Cost of sales subtotal ​ ​ 19.6 ​ ​ ​ 9.1
​ ​ ​ ​ ​ ​ ​ ​
Special (gains) and charges ​ ​ ​ ​ ​ ​ ​
Restructuring activities ​ ​ 3.6 ​ ​ ​ 4.2
Acquisition and integration activities ​ ​ 1.2 ​ ​ ​ 5.4
Disposal and impairment activities ​ ​ - ​ ​ ​ 1.2
COVID-19 activities, net ​ ​ 6.4 ​ ​ ​ -
Other ​ ​ 1.6 ​ ​ ​ 5.1
Special (gains) and charges subtotal ​ ​ 12.8 ​ ​ ​ 15.9
​ ​ ​ ​ ​ ​ ​ ​
Operating income subtotal ​ ​ 32.4 ​ ​ ​ 25.0
​ ​ ​ ​ ​ ​ ​ ​
Total special (gains) and charges ​ ​ $32.4 ​ ​ ​ $25.0

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting.

Restructuring activities

Restructuring activities are primarily related to the Institutional Advancement Program and Accelerate 2020, both of which are described below. Restructuring activities and related costs have been included as a component of both cost of sales and special (gains) and charges on the Consolidated Statement of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheet.

Further details related to our restructuring charges are included in Note 2.

Institutional Advancement Program

We approved a restructuring plan in 2020 focused on the Institutional business (“the Institutional Plan”) which is intended to enhance our Institutional sales and service structure and allow the sales team to capture share and penetration while maximizing service effectiveness by leveraging our ongoing investments in digital technology. In February 2021, we expanded the Institutional Plan. We expect that these restructuring charges will be completed by 2023, with total anticipated costs of $80 million ($60 million after tax) or $0.21 per diluted share. The costs are expected to be primarily cash expenditures for severance and facility closures. We also anticipate non-cash charges related to equipment disposals. We expect total program savings of approximately $50 million by the end of 2024. Actual costs may vary from these estimates depending on actions taken.

In the first quarter of 2021, we have recorded total restructuring charges of $5.9 million ($4.5 million after tax) or $0.02 per diluted share, primarily related to costs to support the transition to the new sales and services structure and the disposal of equipment. We have recorded $41.1 million ($30.9 million after tax), or $0.11 per diluted share of cumulative restructuring charges under the Institutional Plan. The liability related to the Institutional Plan was $15.0 million as of March 31, 2021. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters which continue to be funded from operating activities.

The Institutional Plan has delivered $8 million of cumulative cost savings with estimated annual cost savings of $50 million in continuing operations by 2024.

Accelerate 2020

During 2018, we formally commenced a restructuring plan Accelerate 2020 (“the Plan”), to leverage technology and system investments and organizational changes. The goals of the Plan are to further simplify and automate processes and tasks, reduce complexity and management layers, consolidated facilitates and focus on key long-term growth areas by further leveraging technology and structural improvements. During 2020, we expanded the Plan for additional costs and savings to further leverage the technology and structural improvements. We now expect that the restructuring activities will be completed by the end of 2022, with total anticipated costs of $255 million ($195 million after tax), or $0.68 per diluted share, when revised for continuing operations. The remaining costs are expected to be primarily cash expenditures for severance costs and some facility closure costs relating to team reorganizations. Actual costs may vary from these estimates depending on actions taken.

We recorded restructuring charges of $1.7 million ($1.4 million after tax), or less than $0.01 per diluted share in the first quarter of 2021. The liability related to the Plan was $58.7 million as of the end of the first quarter of 2021. We have recorded $240.9 million ($185.2 million after tax), or $0.64 per diluted share, of cumulative restructuring charges under the Plan. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters and continues to be funded from operating activities. The remaining liability is expected to be paid over a period of several quarters and will continue to be funded from operating activities.

The Plan has delivered $225 million of cumulative cost savings with estimated annual cost savings of $315 million in continuing operations by 2022.

Other Restructuring Activities

During the first quarter of 2021, we incurred restructuring charges of $14.2 million ($10.8 million after tax), or $0.04 per diluted share, related to other immaterial restructuring activity. The charges primarily related to severance. During the first quarter 2021 and 2020, net restructuring charges related to all other prior year plans were minimal.

The restructuring liability balance for all other restructuring plans excluding the Accelerate 2020 and Institutional Plan were $17.1 million and $5.9 million as of March 31, 2021 and December 31, 2020, respectively. The increase in liability was driven by current quarter restructuring charges. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

Cash payments during the first quarter of 2021 related to all other restructuring plans excluding the Accelerate 2020 and Institutional Plan were $0.1 million.

Acquisition and integration related costs

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statement of Income include $1.2 million ($1.1 million after tax) or less than $0.01 per diluted share and $5.4 million ($3.6 million after tax) or $0.01 per diluted share in the first quarter of 2021 and 2020, respectively. Charges in 2021 are related to Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”) and consist of integration costs, advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales on the Consolidated Statement of Income of $0.4 million ($0.3 million after tax) or less than $0.01 per diluted share in the first quarter of 2020, relate to the recognition of fair value step-up in the CID Lines inventory, severance and the closure of a facility.

Disposal and impairment charges

Disposal and impairment charges reported in special (gains) and charges on the Consolidated Statement of Income include $1.2 million ($0.9 million after tax) or less than $0.01 per diluted share in the first quarter of 2020.

Other

During the first quarter of 2021, we recorded charges of $5.9 million, to protect the wages of certain employees directly impacted by the COVID-19 pandemic. We also recorded charges of $3.5 million related to COVID-19 testing and related expenses. In addition, we received subsidies and government assistance, which was recorded as a special (gain) of ($1.9) million during the first quarter of 2021. COVID-19 pandemic charges are recorded in product and equipment sales, service and lease sales, and special (gains) and charges on the Consolidated Statement of Income. Total after tax net charges (gains) related to COVID-19 pandemic were $4.9 million or $0.02 per diluted share during the first quarter of 2021.

During the first quarter of 2020, we recorded special charges of $5.7 million ($3.8 million after tax) or $0.01 per diluted share, in product and equipment cost of sales relates to a Healthcare product recall in Europe. Other special charges recorded in the first quarter of 2021 in product and equipment cost of sales were $0.3 million ($0.2 million after tax) or less than $0.01 per diluted share.

Other special charges of $1.6 million ($1.3 million after tax) or less than $0.01 per diluted share recorded in the first quarter of 2021 related to certain legal charges and tax consulting fees associated with the ChampionX separation.

Other special charges of $6.1 million ($4.6 million after tax) or $0.02 per diluted share recorded in the first quarter of 2020 relate primarily to certain legal charges.

Operating Income and Operating Income Margin

​ ​ ​ (millions) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ First Quarter Ended March 31 2021 2020 ​ ​ ​ Change
Reported GAAP operating income ​ ​ $297.3 ​ ​ ​ $376.2 ​ (21)%
Special (gains) and charges ​ 32.4 ​ ​ 25.0 ​ ​ ​
Non-GAAP adjusted operating income ​ 329.7 ​ ​ 401.2 ​ (18)%
Effect of foreign currency translation ​ 0.5 ​ ​ 7.8 ​ ​ ​
Non-GAAP adjusted fixed currency operating income ​ ​ $330.2 ​ ​ ​ $409.0 ​ (19)%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ First Quarter Ended ​ ​
​ ​ March 31 ​ ​
(percent) ​ 2021 ​ 2020 ​ ​
Reported GAAP operating income margin ​ ​ 10.3% ​ ​ 12.5% ​ ​
Non-GAAP adjusted operating income margin ​ ​ 11.4% ​ ​ 13.3% ​ ​
Non-GAAP adjusted fixed currency operating income margin ​ ​ 11.4% ​ ​ 13.2% ​ ​

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by net sales.

Our reported operating income decreased 21% in the first quarter of 2021, versus the comparable period of 2020. Our reported operating income for 2021 and 2020 was impacted by special (gains) and charges; excluding the impact of special (gains) and charges from 2021 and 2020 reported results, our adjusted operating income decreased 18% in the first quarter of 2021.

As shown in the previous table, foreign currency had a 1% impact on adjusted operating income growth for the first quarter of 2021. Foreign currency had a 0% impact on adjusted operating income growth for the first quarter of 2020.

Other (Income) Expense

Other income was $17.0 million and $15.4 million in the first quarter of 2021 and 2020, respectively. The increase in Other income was driven by higher returns on pension assets.

Interest Expense, Net

Reported net interest expense was $51.7 million and $48.3 million in the first quarter of 2021 and 2020, respectively. The increase in interest expense when comparing 2021 against 2020 was driven primarily by higher average debt levels in this year’s quarter. The increased average debt levels in 2021 include the late March 2020 issuance of debt to further increase our liquidity at the beginning of the COVID-19 pandemic.

Provision for Income Taxes

The following table provides a summary of our tax rate:

​ ​ ​ (percent) ​ ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ 2020
Reported GAAP tax rate ​ 25.2% ​ 13.7%
Tax rate impact of: ​ ​ ​ ​ ​ ​
Special (gains) and charges - ​ ​ 0.8 ​
Discrete tax items (5.5) ​ ​ 6.0 ​
Non-GAAP adjusted tax rate 19.7% ​ 20.5%

Our reported tax rate was 25.2% and 13.7% for the first quarter of 2021 and 2020, respectively. The change in our tax rate for the first quarter of 2021 versus the comparable period of 2020 was driven primarily by discrete tax items. The change in our tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of our historical reported tax rates, as amounts included in our special (gains) and charges are derived from tax jurisdictions with rates that vary from our tax rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future.

We recognized total net tax expense related to discrete tax items of $16.1 million in the first quarter of 2021. This included a non-recurring, non-cash deferred tax charge of $25.1 million associated with transferring certain intangible property between affiliates. The first quarter share-based compensation excess tax benefit was $6.6 million. The amount of this tax benefit is subject to variation in stock price and award exercises. The remaining discrete benefit of $2.4 million was due to other foreign and U.S. changes in estimates during the quarter.

We recognized net discrete tax benefits of $21.9 million in the first quarter of 2020. This includes share-based compensation excess tax benefits of $22.3 million. Additionally, we recognized discrete $3.5 million benefit due to reductions to tax reserves and discrete expense of $3.9 million related to foreign and U.S. changes in estimates.

The decrease in the 2021 first quarter adjusted tax rate compared to 2020 was primarily due to the geographic mix of income and tax planning.

Net Income from Continuing Operations Attributable to Ecolab

​ ​ ​ (millions) ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ 2020 ​ ​ ​ ​ Change
Reported GAAP net income from continuing operations attributable to Ecolab ​ ​ $193.6 ​ ​ ​ $292.0 ​ (34)%
Adjustments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Special (gains) and charges, after tax ​ 24.2 ​ ​ ​ 18.5 ​ ​ ​
Discrete tax net expense (benefit) ​ 16.1 ​ ​ ​ (21.9) ​ ​ ​
Non-GAAP adjusted net income from continuing operations attributable to Ecolab ​ ​ $233.9 ​ ​ ​ $288.6 ​ (19)%

Diluted EPS from Continuing Operations

​ ​ ​ (dollars) ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ 2020 ​ ​ ​ ​ Change
Reported GAAP diluted EPS from continuing operations ​ ​ $0.67 ​ ​ ​ $ 1.00 ​ (33)%
Adjustments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Special (gains) and charges, after tax ​ 0.08 ​ ​ ​ 0.06 ​ ​ ​
Discrete tax net expense (benefit) ​ 0.06 ​ ​ ​ (0.07) ​ ​ ​
Non-GAAP adjusted diluted EPS from continuing operations ​ ​ $0.81 ​ ​ ​ $ 0.99 ​ (18)%

Per share amounts in the above tables do not necessary sum due to rounding.

Currency translation had a favorable impact of approximately $0.02 per share on diluted EPS for the first quarter of 2021, when compared to the comparable periods of 2020.

DISCONTINUED OPERATIONS

The ChampionX business met the criteria to be reported as discontinued operations and the historical results of ChampionX, including the results of operations, are reported as discontinued operations for all periods presented. The net loss from discontinued operations, net of tax was $8.6 million in the first quarter of 2020.

During the second quarter of 2020, in connection with the ChampionX Separation, Ecolab received cash of $527 million and $1,051 million of non-cash consideration of approximately 5.0 million shares of Ecolab common stock for the ChampionX net assets, including cumulative translation adjustment, of $3,717, resulting in a loss.

Special (gains) and charges of $36.5 million in the first quarter of 2020, primarily relate to transaction fees and other professional fees incurred to support the Transaction.

SEGMENT PERFORMANCE

The non-U.S. dollar functional international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates used by management for 2021. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2 of our Annual Report on Form 10-K for the year ended December 31, 2020. Additional information about our reportable segments is included in Note 16.

Fixed currency net sales and operating income for the first quarter of 2021 and 2020 for our reportable segments are shown in the following tables.

​ Net Sales ​ (millions) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ First Quarter Ended March 31 2021 2020 ​ ​ Change
Global Industrial ​ ​ $1,433.9 ​ ​ $1,465.0 ​ (2)%
Global Institutional & Specialty ​ 858.5 ​ ​ 1,087.2 ​ ​ (21) ​
Global Healthcare & Life Sciences ​ ​ 293.7 ​ ​ ​ 256.8 ​ ​ 14 ​
Other ​ ​ 271.3 ​ ​ ​ 279.6 ​ ​ (3) ​
Corporate ​ 33.2 ​ ​ - ​ ​ ​ ​
Subtotal at fixed currency ​ 2,890.6 ​ ​ 3,088.6 ​ ​ (6) ​
Effect of foreign currency translation ​ (5.6) ​ ​ (68.0) ​ ​ ​ ​
Consolidated reported GAAP net sales ​ $2,885.0 ​ ​ ​ $3,020.6 ​ ​ (4)%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating Income ​ First Quarter Ended
​ ​ March 31
(millions) ​ 2021 2020 ​ ​ Change
Global Industrial $219.2 ​ ​ $209.6 ​ 5%
Global Institutional & Specialty ​ 63.1 ​ ​ 183.7 ​ (66) ​
Global Healthcare & Life Sciences ​ ​ 45.6 ​ ​ ​ 24.0 ​ ​ 90 ​
Other ​ 32.9 ​ ​ 21.8 ​ 51 ​
Corporate ​ (63.0) ​ ​ (55.1) ​ ​ ​ ​
Subtotal at fixed currency ​ 297.8 ​ ​ 384.0 ​ (22) ​
Effect of foreign currency translation ​ (0.5) ​ ​ (7.8) ​ ​ ​ ​
Consolidated reported GAAP operating income $297.3 ​ ​ ​ $376.2 ​ (21)%

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

​ ​ ​ Net Sales (millions) ​ ​ ​ ​ ​ ​ ​ ​ ​ First Quarter Ended March 31 2021 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ ​ ​ ​ ​ ​ ​ ​ 2020 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted
Global Industrial ​ $1,433.9 ​ (33.1) ​ $1,400.8 ​ $1,465.0 ​ (17.2) ​ $1,447.8
Global Institutional & Specialty 858.5 ​ (2.9) ​ 855.6 ​ 1,087.2 ​ - ​ 1,087.2
Global Healthcare & Life Sciences ​ 293.7 ​ (2.5) ​ 291.2 ​ 256.8 ​ (0.3) ​ 256.5
Other 271.3 ​ - ​ 271.3 ​ 279.6 ​ - ​ 279.6
Corporate ​ 33.2 ​ (33.2) ​ - ​ - ​ - ​ -
Subtotal at fixed currency 2,890.6 ​ (71.7) ​ 2,818.9 ​ 3,088.6 ​ (17.5) ​ 3,071.1
Effect of foreign currency translation (5.6) ​ ​ ​ ​ ​ (68.0) ​ ​ ​ ​
Total reported net sales $2,885.0 ​ ​ ​ ​ ​ $3,020.6 ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating Income ​ 2021 ​ 2020
(millions) Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted
Global Industrial ​ $219.2 ​ (1.3) ​ $217.9 ​ $209.6 ​ (0.1) ​ $209.5
Global Institutional & Specialty 63.1 ​ 1.0 ​ 64.1 ​ 183.7 ​ - ​ 183.7
Global Healthcare & Life Sciences 45.6 ​ - ​ 45.6 ​ 24.0 ​ - ​ 24.0
Other ​ 32.9 ​ - ​ 32.9 ​ 21.8 ​ - ​ 21.8
Corporate (30.6) ​ - ​ (30.6) ​ (30.1) ​ - ​ (30.1)
Non-GAAP adjusted fixed currency operating income 330.2 ​ (0.3) ​ 329.9 ​ 409.0 ​ (0.1) ​ 408.9
Special (gains) and charges 32.4 ​ ​ ​ ​ ​ 25.0 ​ ​ ​ ​
Subtotal at fixed currency 297.8 ​ ​ ​ ​ ​ 384.0 ​ ​ ​ ​
Effect of foreign currency translation (0.5) ​ ​ ​ ​ ​ (7.8) ​ ​ ​ ​
Total reported operating income $297.3 ​ ​ ​ ​ ​ $376.2 ​ ​ ​ ​

Unless otherwise noted, the following segment performance commentary compares the first quarter of 2021 against the first quarter of 2020.

Global Industrial

​ ​ ​ ​ ​ ​ March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​
Sales at fixed currency (millions) ​ ​ $1,433.9 ​ ​ ​ $1,465.0 ​
Sales at public currency (millions) ​ ​ 1,431.0 ​ ​ ​ 1,433.1 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ (4)% ​ ​ ​
Price changes ​ 1% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ (3)% ​ ​ ​ ​
Acquisitions and divestitures ​ 1% ​ ​ ​
Fixed currency sales change ​ (2)% ​ ​ ​
Foreign currency translation ​ ​ 2% ​ ​ ​ ​
Public currency sales change ​ 0% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $219.2 ​ ​ ​ $209.6 ​
Operating income at public currency (millions) ​ ​ 218.8 ​ ​ ​ 204.8 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ 5% ​ ​ ​ ​
Fixed currency operating income margin ​ 15.3% ​ 14.3%
Acquisition adjusted fixed currency operating income change ​ 4% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 15.6% ​ 14.5%
Public currency operating income change ​ ​ 7% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales for Global Industrial decreased in the first quarter of 2021, reflecting unfavorable impacts in all divisions from supply chain and customer operating disruptions from the Texas freeze during the quarter, most notably in Downstream; excluding those weather-related impacts, Industrial sales are estimated to have improved sequentially and would have been similar to last year.

At an operating segment level, Water fixed currency sales were flat in the first quarter of 2021 as generally improving business trends were negatively impacted by the supply chain and customer operating disruptions due to the Texas freeze. The freeze is estimated to have had a 3 percentage point unfavorable impact on Water sales growth. Excluding the impact of the freeze, both the Light and Heavy industry water treatment businesses showed strong growth. Mining declined primarily reflecting coal-related business exits and supply chain disruptions. Food & Beverage fixed currency sales increased 2%, but decreased 2% acquisition adjusted, in the first quarter of 2021 reflecting COVID-19 related impacts that benefited customer demand last year but hurt the first quarter as further lockdowns were put in place, particularly in Europe, reducing beverage and brewing demand and production. Globally, we realized modest growth in beverage and brewery sales and stable dairy plant sales but saw COVID-19 related declines in other business lines. Downstream fixed currency sales decreased 17% in the first quarter of 2021. The Texas freeze is estimated to have had a negative 5 percentage point impact on Downstream sales growth due to unplanned North America customer outages and supply shortages from the freeze. Excluding the impact from the Texas freeze, higher petrochemical sales were more than offset by continued lower refinery sales as production remained low. Paper fixed currency sales increased 2% in the first quarter of 2021, as strong international gains more than offset impacts from the Texas freeze; the freeze is estimated to have had a 2 percentage point negative impact on Paper sales growth. Board & packaging along with tissue & towel end markets led the increase, while graphics posted a modest decline.

Operating Income

Fixed currency operating income and fixed currency operating income margins increased for Global Industrial in the first quarter of 2021.

Acquisition adjusted fixed currency operating income margins increased 1.1 percentage points during the first quarter of 2021 and were positively impacted approximately 2.5 percentage points in the first quarter of 2021 by cost savings and favorable pricing, which more than offset the estimated 1.7 percentage point negative impact of lower volume from the Texas freeze during the first quarter of 2021.

Global Institutional & Specialty

​ ​ ​ ​ ​ ​ March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​
Sales at fixed currency (millions) ​ ​ $858.5 ​ ​ ​ $1,087.2 ​
Sales at public currency (millions) ​ ​ 857.4 ​ ​ ​ 1,070.1 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ (23)% ​ ​ ​
Price changes ​ 2% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ (21)% ​ ​ ​ ​
Acquisitions and divestitures ​ -% ​ ​ ​
Fixed currency sales change ​ (21)% ​ ​ ​
Foreign currency translation ​ ​ 1% ​ ​ ​ ​
Public currency sales change ​ (20)% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $63.1 ​ ​ ​ $183.7 ​
Operating income at public currency (millions) ​ ​ 63.2 ​ ​ ​ 182.0 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ (66)% ​ ​ ​ ​
Fixed currency operating income margin ​ 7.4% ​ 16.9%
Acquisition adjusted fixed currency operating income change ​ (65)% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 7.5% ​ 16.9%
Public currency operating income change ​ ​ (65)% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales for Global Institutional & Specialty decreased in the first quarter of 2021 driven by the unfavorable impact of COVID-19’s strong second wave, as continued sanitizing product sales were more than offset by continued global demand pressure on restaurant, lodging and entertainment facilities for other products due to the pandemic during most of the quarter.

At an operating segment level, Institutional fixed currency sales decreased 25% in the first quarter of 2021, narrowing from the fourth quarter decrease, despite ongoing COVID-19 related restrictions which negatively impacted the first part of the quarter. While hand and surface hygiene sales remained strong relative to pre-COVID levels, continued mandated restrictions for in-unit dining, especially in Europe, and travel concerns during the quarter negatively impacted foot traffic at full-service restaurants, occupancy rates at hotels and customer visits to entertainment facilities. Specialty fixed currency sales decreased 9% in the first quarter of 2021, reflecting comparison to the very strong first quarter 2020, where strong COVID-19 driven buying significantly boosted sales. Adjusted for COVID-19 related product sales in both periods, first quarter 2021 sales are estimated to have increased 1 percentage point. Adjusted for those product sales, estimated quickservice revenues increased modestly as new customer wins were mostly offset by reduced in-unit dining foot traffic due to COVID-related lockdowns, most notably in Europe. Adjusted food retail sales are also estimated to have increased modestly with expanded cleaning protocols, new customer additions and product and program introductions.

Operating Income

Fixed currency operating income and fixed currency operating income margins decreased for our Global Institutional & Specialty segment in the first quarter of 2021.

Acquisition adjusted fixed currency operating income margins decreased 9.4 percentage points during the first quarter of 2021. Margins were negatively impacted approximately 13.8 percentage points in the first quarter of 2021 from significant COVID-19 related volume declines and unfavorable business mix, which more than offset the approximately 4.5 percentage point positive impact of cost savings and favorable pricing during the first quarter of 2021.

Global Healthcare & Life Sciences

​ ​ ​ ​ ​ ​ First Quarter Ended 2021 ​ ​ ​ ​ ​ 2020 ​ ​
Sales at fixed currency (millions) ​ ​ $293.7 ​ ​ ​ $256.8 ​
Sales at public currency (millions) ​ ​ 292.7 ​ ​ ​ 244.7 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ 12% ​ ​ ​
Price changes ​ 2% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ 14% ​ ​ ​ ​
Acquisitions and divestitures ​ 1% ​ ​ ​
Fixed currency sales change ​ 14% ​ ​ ​
Foreign currency translation ​ ​ 5% ​ ​ ​ ​
Public currency sales change ​ 20% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $45.6 ​ ​ ​ $24.0 ​
Operating income at public currency (millions) ​ ​ 45.4 ​ ​ ​ 22.5 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ 90% ​ ​ ​ ​
Fixed currency operating income margin ​ 15.5% ​ 9.3%
Acquisition adjusted fixed currency operating income change ​ 90% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 15.7% ​ 9.4%
Public currency operating income change ​ ​ 102% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales for the Global Healthcare & Life Sciences increased in the first quarter of 2021, benefiting from new business and continued demand due to COVID-19.

At an operating segment level, Healthcare fixed currency sales increased 13% (12% acquisition adjusted) in the first quarter of 2021, as strong COVID-19 related hand and surface disinfection sales growth continued to more than offset the unfavorable effects of delayed elective surgical procedures. Life Sciences fixed currency sales increased 18% (19% acquisition adjusted) in the first quarter of 2021, as the stronger than normal growth continued to be driven by heightened COVID-19 concerns, higher cleaning standards and increased demand for our Bioquell biodecontamination systems and offerings, as well as ongoing business wins and pricing.

Operating Income

Fixed currency operating income and fixed currency operating income margins for our Global Healthcare & Life Sciences segment increased in the first quarter of 2021.

Acquisition adjusted fixed currency operating income margins increased 6.3 percentage points during the first quarter of 2021. Strong volume gains, favorable pricing and cost savings positively impacted margins by approximately 6.9 percentage points during the first quarter of 2021.

Other

​ ​ ​ ​ ​ ​ March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​
Sales at fixed currency (millions) ​ ​ $271.3 ​ ​ ​ $279.6 ​
Sales at public currency (millions) ​ ​ 270.7 ​ ​ ​ 272.7 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ (5)% ​ ​ ​
Price changes ​ 2% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ (3)% ​ ​ ​ ​
Acquisitions and divestitures ​ -% ​ ​ ​
Fixed currency sales change ​ (3)% ​ ​ ​
Foreign currency translation ​ ​ 2% ​ ​ ​ ​
Public currency sales change ​ (1)% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $32.9 ​ ​ ​ $21.8 ​
Operating income at public currency (millions) ​ ​ 32.8 ​ ​ ​ 21.3 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ 51% ​ ​ ​ ​
Fixed currency operating income margin ​ 12.1% ​ 7.8%
Acquisition adjusted fixed currency operating income change ​ 51% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 12.1% ​ 7.8%
Public currency operating income change ​ ​ 54% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales for Other decreased in the first quarter of 2021 as a solid increase in Pest Elimination was more than offset by declines in the remaining Other segments.

At an operating segment level, Pest Elimination fixed currency sales increased 5% in the first quarter of 2021, as good growth in food and beverage plants, grocery stores and quick service restaurant sales and new business more than offset lower full service restaurant and hospitality sales that were negatively impacted by capacity restrictions. Textile Care fixed currency sales decreased 23% in the first quarter of 2021. Colloidal Technologies Group fixed currency sales decreased 6% in the first quarter of 2021.

Operating Income

Acquisition adjusted fixed currency operating income margins for Other increased 4.3 percentage points during the first quarter of 2021. Cost savings, favorable pricing and favorable business mix positively impacted margins by approximately 5.8 percentage points for the first quarter of 2021. These margin increases more than offset lower volumes which negatively impacted margins by approximately 1.8 percentage points for the first quarter of 2021.

Corporate

Consistent with our internal management reporting, Corporate amounts in the table on page 39 include sales to ChampionX in accordance with the long-term supply agreement entered into with the Transaction post-separation, as discussed in Note 4, intangible asset amortization specifically from the Nalco merger and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 35.

FINANCIAL POSITION, CASH FLOWS AND LIQUIDITY

Financial Position

Total assets were $18.2 billion as of March 31, 2021 compared to total assets of $18.1 billion as of December 31, 2020.

Total liabilities were $11.9 billion as of March 31, 2021 compared to total liabilities of $11.9 billion as of December 31, 2020. Total debt was $6.7 billion as of March 31, 2021 and $6.7 billion as of December 31, 2020. See further discussion of our debt activity within the “Liquidity and Capital Resources” section of this MD&A.

Our net debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”) is shown in the following table. EBITDA is a non-GAAP measures discussed further in the “Non-GAAP Financial Measures” section of this MD&A.

The inputs to EBITDA reflect the trailing twelve months of activity for the period presented.

​ ​ (ratio) ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ ​
Net debt to EBITDA ​ 2.5 ​ ​ 2.4 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
(millions) ​ ​ ​ ​ ​ ​ ​
Total debt ​ ​ $6,710.1 ​ ​ ​ $6,686.6 ​
Cash ​ 1,189.5 ​ ​ ​ 1,260.2 ​
Net debt ​ ​ $5,520.6 ​ ​ ​ $5,426.4 ​
​ ​ ​ ​ ​ ​ ​ ​ ​
Net income including noncontrolling interest ​ ​ $885.0 ​ ​ ​ $984.8 ​
Provision for income taxes ​ 195.7 ​ ​ ​ 176.6 ​
Interest expense, net ​ 293.6 ​ ​ ​ 290.2 ​
Depreciation ​ 598.6 ​ ​ ​ 594.3 ​
Amortization ​ 230.6 ​ ​ ​ 218.4 ​
EBITDA ​ $2,203.5 ​ ​ ​ $2,264.3 ​

Cash Flows

Operating Activities

​ ​ ​ (millions) ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ Change ​ ​
Cash provided by operating activities ​ ​ $295.3 ​ ​ ​ $308.3 ​ ​ ​ ($13.0) ​

We continue to generate cash flow from operations, amidst the COVID-19 pandemic, allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases. Cash provided by operating activities decreased $13 million in the first quarter of 2021 compared to the first quarter of 2020, driven primarily by a $100 million reduction in net income from continuing operations including noncontrolling interest, partially offset by $45 million net favorable fluctuations in deferred taxes and $44 million net favorable fluctuations in accounts receivable, inventories and accounts payable (“working capital”). The cash flow impact from working capital accounts was primarily driven by improvements in days sales outstanding.

Investing Activities

​ ​ ​ (millions) ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ Change ​ ​
Cash used for investing activities ​ ​ ($192.4) ​ ​ ​ ($153.3) ​ ​ ​ ($39.1) ​

Cash used for investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as capital investments in the business.

Total cash paid for acquisitions, net of cash acquired along with net cash received from dispositions, during the first quarter of 2021 and 2020, was $88 million and $2 million, respectively. Our acquisitions and divestitures are discussed further in Note 3. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

We continue to make capital investments in the business, including merchandising equipment, manufacturing equipment and facilities. Total capital expenditures were $102 million and $148 million in the first quarter of 2021 and 2020, respectively.

Financing Activities

​ ​ ​ (millions) ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ Change ​ ​
Cash (used for) provided by financing activities ​ ​ ($183.1) ​ ​ ​ $1,264.5 ​ ​ ​ ($1,447.6) ​

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

We issued $764 million of long-term debt and repaid $300 million of long-term debt in the first quarter of 2020. The proceeds received from the debt issuances were used for repayment of outstanding debt, repayment of commercial paper and general corporate purposes. In addition, we had net issuances of commercial paper and notes payable of $6 million and $958 million in the first quarter of 2021 and 2020, respectively.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans and stock issued in acquisitions, to manage our capital structure and to efficiently return capital to shareholders. We reacquired a total of $62 million and $95 million of shares in the first quarter of 2021 and 2020, respectively. Cash proceeds and tax benefits from stock option exercises provide a portion of the funding for repurchase activity.

The impact on financing cash flows of commercial paper and notes payable issuances and long-term debt borrowings and repayments are shown in the following table:

​ ​ ​ (millions) ​ ​ ​ ​ ​ First Quarter Ended March 31 2021 ​ ​ ​ ​ ​ 2020 ​ ​ ​ ​ Change ​ ​
Net issuances of commercial paper and notes payable ​ ​ $5.8 ​ ​ ​ $957.6 ​ ​ ​ ($951.8) ​
Long-term debt borrowings ​ ​ - ​ ​ ​ 763.7 ​ ​ ​ (763.7) ​
Long-term debt repayments ​ ​ - ​ ​ ​ (299.7) ​ ​ ​ 299.7 ​

Liquidity and Capital Resources

We currently expect to fund the cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

As of March 31, 2021, we had $1,190 million of cash and cash equivalents on hand, of which $68 million was held outside of the U.S. We continue to carry increased levels of cash on hand to meet current and any future potential operational cash needs as a result of the COVID-19 pandemic. We will continue to evaluate our cash position in light of future developments.

As of March 31, 2021, we have a $2.0 billion multi-year credit facility which was scheduled to expire in November 2022. In April 2021, we entered into an amended and restated revolving credit facility which extended the maturity from November 2022 to April 2026. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At the end of the first quarter of 2021, we had no outstanding commercial paper under our U.S. or Euro programs. There were no borrowings under our credit facility as of March 31, 2021 or 2020. As of March 31, 2021, both programs were rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

As of March 31, 2021, we had a $500 million 364-day revolving credit agreement which expired in April 2021. The credit agreement had been established with a diverse syndicate of banks. There were no borrowings under this revolving credit agreement as of March 31, 2021.

Our long-term debt issuance and repayment activity through the first quarter of 2021 and 2020 is discussed in the Cash Flows – Financing Activities section of this MD&A.

We are in compliance with our debt covenants and believe we have sufficient borrowing capacity to meet our foreseeable operating activities, as needed.

The schedule of contractual obligations included in the Financial Position and Liquidity section of our Form 10-K for the year ended December 31, 2020 disclosed total notes payable and long-term debt due within one year of $17 million. As of March 31, 2021, the total notes payable and long-term debt due within one year increased to $24 million. There was no commercial paper outstanding as of March 31, 2021 or December 31, 2020.

Our gross liability for uncertain tax positions was $20 million as of March 31, 2021 and $21 million as of December 31, 2020. We are not able to reasonably estimate the amount by which the liability will increase or decrease over time; however, at this time, we do not expect significant payments related to these obligations within the next year.

GLOBAL ECONOMIC ENVIRONMENT

Coronavirus disease 2019 (COVID-19)

In March 2020, the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. The COVID-19 pandemic is continuing to affect major economic and financial markets, while industries are facing the challenges with the economic conditions resulting from efforts to address the pandemic. As the spread of the pandemic continues, many countries have required companies to limit or suspend business operations and have implemented travel restrictions. These conditions have had and will continue to have a negative impact on market conditions and customer demand throughout the world. We believe developing though still uneven improvements in global COVID-19 trends provide an overall encouraging outlook for the world and our end markets in 2021; however, the ongoing effects of the global COVID-19 outbreak could result in a global recession.

In the second quarter of 2021, we look for very strong growth versus our second quarter last year, primarily driven by very significant growth in our Institutional division where we have seen improving trends in early-reopening U.S. states, and we expect continued robust consolidated gains in the second half provided the COVID-10 pandemic continues to wane. We remain confident in our long-term outlook and believe we are well-positioned for continued future growth.

Global Economies

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results.

Argentina has continued to experience negative economic trends, evidenced by multiple periods of increasing inflation rates, devaluation of the peso, and increasing borrowing rates. Argentina is classified as a highly inflationary economy in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina. During the first quarter of 2021, sales in Argentina represented less than 1% of our consolidated sales. Assets held in Argentina at the end of the first quarter of 2021 represented less than 1% of our consolidated assets.

NEW ACCOUNTING PRONOUNCEMENTS

For information on new accounting pronouncements, refer to Note 18 to the Consolidated Financial Statements.

SUBSEQUENT EVENT

In April 2021, we entered into an amended and restated the $2.0 billion multi-currency revolving credit facility which extended the maturity from November 2022 to April 2026.

NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

  • Fixed currency sales
  • Acquisition adjusted fixed currency sales
  • Adjusted cost of sales
  • Adjusted gross margin
  • Fixed currency operating income
  • Fixed currency operating income margin
  • Adjusted operating income
  • Adjusted operating income margin
  • Adjusted fixed currency operating income
  • Adjusted fixed currency operating income margin
  • Acquisition adjusted fixed currency operating income
  • Acquisition adjusted fixed currency operating income margin
  • Adjusted interest expense, net
  • EBITDA
  • Adjusted tax rate
  • Adjusted net income attributable to Ecolab
  • Adjusted diluted EPS

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measures for cost of sales, gross margin and operating income exclude the impact of special (gains) and charges, and our non-GAAP measures for tax rate, net income attributable to Ecolab and diluted EPS further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as the sum of net income including noncontrolling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange. Fixed currency amounts included in this Form 10-Q are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2021.

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition, exclude the results of our divested businesses from the twelve months prior to divestiture.

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP, and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the COVID-19 pandemic outlook; business performance and prospects; expectations concerning timing, amount and type of restructuring costs and savings from restructuring activities; tax deductibility of goodwill; capital investments and acquisitions; amortization expense; non-performance of financial counterparties; payments and contributions to pension and postretirement health care benefit plans; the impact of lawsuits, claims and environmental matters; impact of new accounting pronouncements; cash flows, borrowing capacity and funding of cash requirements; payments related to uncertain tax positions; and implementation of ERP system upgrade.

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof) or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. In particular, the effects of the COVID-19 pandemic depend on numerous factors, including the severity of the disease, the duration of the outbreak, the distribution and efficacy of vaccines, the likelihood of a resurgence of the outbreak, actions that may be taken by governmental authorities intended to minimize the spread of the pandemic or to stimulate the economy and other unintended consequences. Further, the ultimate results of any restructuring or efficiency initiative, integration and business improvement actions, including cost synergies, depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring or efficiency initiative and other business improvement initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made.

Some of the factors which could cause results to differ materially from those expressed in any forward-looking statements are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the Securities and Exchange Commission (the "SEC"), and include the effects of the COVID-19 pandemic; the vitality of the markets we serve; the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk and reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar; our ability to execute key business initiatives, including restructurings and our Enterprise Resource Planning system upgrades; potential information technology infrastructure failures or breaches in data security; potential to incur significant tax liabilities or indemnification liabilities relating to the separation and split-off of our ChampionX business; our ability to attract, retain and develop high caliber management talent to lead our business and successfully execute organizational change; our ability to successfully compete with respect to value, innovation and customer support; exposure to global economic, political and legal risks related to our international operations; difficulty in procuring raw materials or fluctuations in raw material costs; pressure on operations from consolidation of customers or vendors; the costs and effects of complying with laws and regulations, including those relating to the environment, and to the manufacture, storage, distribution, sale and use of our products, as well as to the conduct of our business generally, including labor and employment and anti-corruption; restraints on pricing flexibility due to contractual obligations; our ability to acquire complementary businesses and to effectively integrate such businesses; changes in tax laws and unanticipated tax liabilities; potential loss of deferred tax assets; our indebtedness, and any failure to comply with covenants that apply to our indebtedness; public health outbreaks, epidemics or pandemics, such as the current outbreak of COVID-19; potential losses arising from the impairment of goodwill or other assets; potential chemical spill or release; the occurrence of litigation or claims, including class action lawsuits; the loss or insolvency of a major customer or distributor; repeated or prolonged government and/or business shutdowns or similar events; acts of war or terrorism; natural or man-made disasters; water shortages; severe weather conditions; and other uncertainties or risks reported from time to time in our reports to the SEC. There can be no assurances that our earnings levels will meet investors’ expectations. Except as may be required under applicable law, we do not undertake, and expressly disclaim, any duty to update our Forward-Looking Statements.

Market risk

As filed, 555 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We use foreign currency forward contracts, interest rate swap agreements and foreign currency debt to manage risks associated with foreign currency exchange rates, interest rates and net investments in our foreign operations. We do not hold derivative financial instruments of a speculative nature or for trading purposes. For a more detailed discussion of derivative instruments, refer to Note 9, entitled “Derivatives and Hedging Transactions”, of the consolidated financial statements located under Part I, Item 1 of this quarterly report on Form 10-Q.

Controls and procedures

As filed, 1,225 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of March 31, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are effective.

During the period January 1, 2021 through March 31, 2021, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continuing our implementation of our enterprise resource planning (“ERP”) system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

Risk factors

As filed, 769 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In our report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 26, 2021, we identify under Item 1A important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-Q. See the section entitled Forward-Looking Statements located on page 48 of this Form 10-Q. We may also refer to such disclosure to identify factors that may cause results to differ from those expressed in other forward-looking statements made in oral presentations, including telephone conferences and/or webcasts open to the public.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-01-01 to 2021-03-31$2.88bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-01-01 to 2021-03-31$1.71bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2021-01-01 to 2021-03-31$862.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-01-01 to 2021-03-31$297.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-01-01 to 2021-03-31$53.8mus-gaap:InterestExpense
Income tax3 months2021-01-01 to 2021-03-31$66.1mus-gaap:IncomeTaxExpenseBenefit
Diluted EPS3 months2021-01-01 to 2021-03-31$0.67us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-01-01 to 2021-03-31$0.68us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-01-01 to 2021-03-31288,800,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2021-01-01 to 2021-03-31$295.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-01-01 to 2021-03-31$102.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2021-01-01 to 2021-03-31$146.7mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases3 months2021-01-01 to 2021-03-31$61.8mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-03-31$1.19bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-03-31$5.15bnus-gaap:AssetsCurrent
Total assetsAt period end2021-03-31$18.21bnus-gaap:Assets
Current liabilitiesAt period end2021-03-31$2.85bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-03-31$11.89bnus-gaap:Liabilities
Current portion of debtAt period end2021-03-31$24.3mus-gaap:DebtCurrent
Shareholders' equityAt period end2021-03-31$6.29bnus-gaap:StockholdersEquity
Shares outstandingAt period end2021-03-31285,937,396 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001558370-21-006198. Last ingested by Listed: Nov 13, 2026, 16:24 ET. Listed shows no prices and gives no investment advice.